Needham Thinks LivaNova’s Stock is Going to Recover

In a report released today, Michael Matson from Needham maintained a Buy rating on LivaNova (LIVNResearch Report), with a price target of $106.00. The company’s shares closed last Friday at $60.60, close to its 52-week low of $56.13.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 3.3% and a 47.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LivaNova with a $102.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on LivaNova’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $240 million and net profit of $2.99 million. In comparison, last year the company earned revenue of $248 million and had a GAAP net loss of $30.76 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company’s shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.

Read More on LIVN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More